Trials / Completed
CompletedNCT06272747
Study of XH-S003 in Healthy Volunteers
A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of XH-S003 After Single Ascending Doses, Multiple Ascending Doses and Evaluation of Food Effects in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- S-INFINITY Pharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess the safety, tolerability and pharmacokinetics of XH-S003 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending dose) studies. In addition, this study evaluates the food effects of XH-S003.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XH-S003 | IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral |
| DRUG | Placebo | Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral |
Timeline
- Start date
- 2023-07-10
- Primary completion
- 2024-07-30
- Completion
- 2024-11-30
- First posted
- 2024-02-22
- Last updated
- 2025-05-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06272747. Inclusion in this directory is not an endorsement.